Clinical development failure
Haduvio must prove safety and efficacy across target cough indications before approval.
- Scope
- Phase 3, Phase 2b, and supportive studies
- Materiality
- high
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing Haduvio, an oral therapy for chronic cough and related respiratory conditions. The company’s work centers on clinical development, regulatory approval, and eventual commercialization of Haduvio in the United States and through partners outside the U.S.
19.66
19.66
| % | |
|---|---|
| Haduvio clinical development | 100% Clinical-stage development of Haduvio across respiratory cough indications. |
| Regulatory and approval pathway | 0% Activities supporting FDA and other regulatory submissions for Haduvio. |
| Future commercialization | 0% Planned U.S. and ex-U.S. commercialization of approved Haduvio products. |
Trevi does not currently sell commercial products; its eventual customers would be physicians, patients, and payors in...
- Pulmonologistsprimary
Specialists who would prescribe Haduvio for IPF and non-IPF ILD-related chronic cough.
- Refractory chronic cough specialistsprimary
Pulmonologists and allergists treating RCC patients who have failed other therapies.
- Third-party payorsprimary
Insurers and government payors that decide coverage and reimbursement levels.
- Patients with chronic coughprimary
End users of the therapy, especially those with IPF, non-IPF ILD, or RCC.
- Ex-U.S. commercial partnerssecondary
Potential collaborators that would help market and distribute Haduvio outside the U.S.
Trevi is headquartered in the United States and expects initial commercialization of Haduvio to be U.S.-focused...
- •Headquartered in the United States
- •Planned initial commercialization is U.S.-focused
- •Ex-U.S. sales would likely rely on third-party partners
- •Regulatory approval is needed in each target market
- •Global expansion depends on local reimbursement and market access
Trevi’s strategy is to advance Haduvio through late-stage clinical development, secure regulatory approval, and build a...
01
Complete late-stage clinical development of Haduvioshort-term
Approval depends on demonstrating safety and efficacy in target cough populations.
02
Prepare for U.S. commercializationmedium-term
A focused specialty sales model is needed if the product is approved.
03
Secure reimbursement and market accessmedium-term
Coverage and reimbursement will determine whether the product can be adopted at scale.
04
Protect intellectual property and supply chain readinesslong-term
Patent protection and reliable manufacturing support long-term commercial value.
Trevi is a clinical-stage company with no product sales, so its value depends on successful development, approval, and...
Regulatory approval risk
FDA and other authorities may require more data, delay approval, or reject applications.
- Scope
- IPF, non-IPF ILD, and RCC programs
- Materiality
- high
Financing risk
The company expects to fund operations through external capital until product revenue exists.
- Scope
- Equity, debt, collaborations, strategic transactions
- Materiality
- high
Reimbursement and pricing risk
Payors may restrict coverage or require pricing concessions, limiting adoption.
- Scope
- U.S. and international market access
- Materiality
- high
Manufacturing and third-party dependence
Drug substance and finished product supply rely on external vendors and cGMP compliance.
- Scope
- CROs, contract manufacturers, drug substance suppliers
- Materiality
- medium
Intellectual property risk
Patent scope, validity, and foreign protection affect exclusivity and long-term value.
- Scope
- U.S. and foreign patent portfolios
- Materiality
- medium
Research and development accruals
Can shift reported R&D expense between periods
Stock-based compensation
Affects operating loss and non-cash reconciliation
Marketable securities valuation
Can affect reported investment gains/losses
Lease accounting
Affects balance sheet and operating expense presentation
Future revenue recognition and deductions
Will affect net product revenue and margins
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Traws Pharma, Inc.
TRAW · Pharmaceutical Preparations
BIOVIE INC.
BIVI · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
: 29/04/2026